Company Overview
Digital health platform that helps people access their medications, get doorstep delivery, automate monthly refills, enjoy free follow-ups and connect with healthcare providers.
Company History
Famasi was founded in 2021. Public founder information in the source set points to Adeola Ayoola, Umar Faruq Akinwunmi. Its latest captured funding/news event in the source set was in 2023, recorded as Pre-Seed.
Key Facts
| Country | Nigeria |
| Founded | 2021 |
| Founders | Adeola Ayoola, Umar Faruq Akinwunmi |
| Sector | Healthcare |
| Operational Status | Likely active / unverified |
| Latest Round | Pre-Seed, 2023, $0.1M |
| Total Disclosed Funding | $0.1M |
| Website | https://www.famasi.africa/ |
Business Model
Famasi appears to operate a product-led business model in the Healthcare sector. Based on public descriptions, it generates value through technology-enabled services, software, marketplace access, operations, or financial infrastructure.
Products and Services
- Pharmaceutical or care infrastructure
- Hospital or provider digitisation
- Supply-chain services
- Patient access tools
Funding and Market Position
Public deal records in the source set show 1 disclosed funding event(s), with about $0.1M captured in total. The most recent event is recorded as Pre-Seed, 2023, $0.1M.
Contact Information
The most reliable public contact channel in the source set is the official website: https://www.famasi.africa/. Public phone numbers and public support emails were not consistently available at scale, so the website/contact form is the best public route.
Company Location
Operational Status
Public sources show activity in 2023, did not independently verify current operations beyond the source set. Status recorded here is a best-effort assessment as of March 21, 2026.
Why This Startup Matters
As a Nigerian startup in the Healthcare space, Famasi matters because it addresses local market problems with a scalable digital product or operational model.
Sources
Related Startups
- RxAll
- Platos Health
- Myltura

